Eidos Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported loss from operations of $12,584,000 against $7,997,000 a year ago. Net loss attributable to common stockholders was $11,733,000 against $7,963,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.32 against $1.81 a year ago.